enGene Therapeutics (ENGN) Capital Expenditures (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Capital Expenditures of $98000.0 for Q2 2026, up 117.78% year-over-year from $45000.0 in Q2 2025, and down 35.95% quarter-over-quarter from $153000.0 in Q1 2026.
enGene Therapeutics (ENGN) Capital Expenditures (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Capital Expenditures for 4 consecutive years, with $98000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Capital Expenditures rose 117.78% year-over-year to $98000.0; the TTM figure through Apr 2026 stood at $239000.0 (down 59.08% YoY), while the FY2025 annual figure was $332000.0, down 64.11% from the prior year.
- Capital Expenditures eased to $98000.0 in Q2 2026 per ENGN's latest filing, from $153000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $704000.0 in Q3 2025 and bottomed at -$716000.0 in Q4 2025.
- Historically, Capital Expenditures has averaged $130428.6 across 4 years, with a median of $145500.0 in 2023.
- On a YoY basis, Capital Expenditures climbed as much as 35100.0% in 2025 and fell as far as 400.84% in 2025.
- enGene Therapeutics' Capital Expenditures stood at $138000.0 in 2023, then jumped by 72.46% to $238000.0 in 2024, then plunged by 400.84% to -$716000.0 in 2025, then soared by 113.69% to $98000.0 in 2026.
- Business Quant data shows ENGN's Capital Expenditures at $98000.0 in Q2 2026, $153000.0 in Q1 2026, and -$716000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 98,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 98,000.00 |
| Apr 30, 2026 | 98,000.00 |
| Jan 31, 2026 | 153,000.00 |
| Jan 31, 2026 | 153,000.00 |
| Oct 31, 2025 | -716,000.00 |
| Oct 31, 2025 | -716,000.00 |
| Jul 31, 2025 | 704,000.00 |
| Jul 31, 2025 | 704,000.00 |
| Apr 30, 2025 | 45,000.00 |
| Apr 30, 2025 | 45,000.00 |
| Jan 31, 2025 | 299,000.00 |
| Jan 31, 2025 | 299,000.00 |
| Oct 31, 2024 | 238,000.00 |
| Oct 31, 2024 | 238,000.00 |
| Jul 31, 2024 | 2,000.00 |
| Jul 31, 2024 | 2,000.00 |
| Apr 30, 2024 | 179,000.00 |
| Apr 30, 2024 | 179,000.00 |
| Jan 31, 2024 | 506,000.00 |
| Jan 31, 2024 | 506,000.00 |